Anti-Plasminogen antibody (Biotin) (ab7335)


  • Product nameAnti-Plasminogen antibody (Biotin)
    See all Plasminogen primary antibodies
  • Description
    Goat polyclonal to Plasminogen (Biotin)
  • ConjugationBiotin
  • Tested applicationsSuitable for: Conjugation, Dot Blot, ELISA, IHC-Fr, Immunomicroscopy, WB, Flow Cyt, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Plasminogen [Human Plasma]

  • General notes

    Biotinamidocaproate N-Hydroxysuccinimide Ester (BAC) Biotin/Protein Ratio: 10-20 BAC molecules per goat IgG molecule.



Our Abpromise guarantee covers the use of ab7335 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Conjugation Use at an assay dependent concentration.
Dot Blot Use at an assay dependent concentration.
ELISA Use at an assay dependent concentration.

as well as other antibody based assays using streptavidin or avidin conjugates requiring lot-to-lot consistency.

IHC-Fr Use at an assay dependent concentration.
Immunomicroscopy Use at an assay dependent concentration.
WB Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration. PubMed: 19182206


  • FunctionPlasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
    Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
  • Tissue specificityPresent in plasma and many other extracellular fluids. It is synthesized in the liver.
  • Involvement in diseaseDefects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
    Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
  • Sequence similaritiesBelongs to the peptidase S1 family. Plasminogen subfamily.
    Contains 5 kringle domains.
    Contains 1 PAN domain.
    Contains 1 peptidase S1 domain.
  • DomainKringle domains mediate interaction with CSPG4.
  • Post-translational
    N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
    In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
  • Cellular localizationSecreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
  • Information by UniProt
  • Database links
  • FormCleaved into the following 5 chains: 1.Plasmin heavy chain A2.Activation peptide3.Angiostatin4.Plasmin heavy chain A, short form5. Plasmin light chain B
  • Alternative names
    • Angiostatin antibody
    • DKFZp779M0222 antibody
    • Plasmin antibody
    • Plasmin heavy chain A antibody
    • Plasmin light chain B antibody
    • Plasminogen antibody
    • PLG antibody
    • PLMN_HUMAN antibody
    see all

References for Anti-Plasminogen antibody (Biotin) (ab7335)

This product has been referenced in:
  • Wygrecka M  et al. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 113:5588-98 (2009). WB, ICC/IF, IHC-Fr ; Human . Read more (PubMed: 19182206) »

See 1 Publication for this product

Product Wall

Thank you for contacting us back.

Your Abreview has already been published, and the discount code then automatically activated. You can now place the order indicating the discount code on it.

It is crucial to mention the discount co...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Flow Cytometry
Sample Human Cell (muscle,rhabdomyosarcoma)
Specification muscle,rhabdomyosarcoma
Preparation Cell harvesting/tissue preparation method: the cell were trypsinized and counted to 5x10^5 cell/ each group
Sample buffer: FACS buffer
Fixation No
Permeabilization No
Gating Strategy the cells were gated on FSC/SSC to remove cell debris

Dr. Chang Chuan-Fa

Verified customer

Submitted Feb 07 2012